

Short Communication

NETARSUDIL – A REVIEW

ABSTRACT:

Glaucoma currently affecting over 60 million people worldwide continues to be the leading cause of irreversible blindness. A novel topical ocular hypotensive glaucoma medication – Netarsudil effectiveness need to be assessed. Methods: Netarsudil was evaluated in three randomized and controlled trials, in patients with open angle glaucoma or ocular hypertension. Study 1 & 2 enrolled the subjects with baseline IOP < 27mmhg and study 3 enrolled subjects with base line IOP < 30 mmhg. Result: Netarsudil effect was analysed in all the participants. Conclusion: Netarsudil has a unique mechanism of action through which it **lowers the Netarsudil has a unique mechanism of action through which it** lowers the intraocular pressure.

Keywords: Netarsudil; Drug effect; intraocular pressure.

Introduction: Worldwide, Glaucoma affecting over 60 million people and continues to be the leading cause of irreversible blindness. Medical intervention is the preliminary therapy to progression of optic nerve damage and vision loss prevention by reducing the IOP. IOP is the regulated balance between production of aqueous humor and the rate of aqueous flow via uveoscleral outflow pathway and trabecular meshwork pathway(TM). A new ocular hypotensive glaucoma medication through topical route – Netarsudil is approved by the FDA in December 2017².

Mechanism of Action: Netarsudil is a potent inhibitor of ROCK and also NET. ROCK is a serine/threonine protein kinase which accelerates the actin stress fibres assembly and focal adhesion within the trabecular meshwork. Netarsudil acts by three novel mechanisms for lowering Intraocular pressure². First is it lowers the IOP by relaxation of TM and ciliary muscle contraction which leads to increase in the outflow of aqueous by the conventional method². Second, by ROCK1 & ROCK2 inhibition which are usually present in higher amounts in the trabecular meshwork. Lastly by decreasing the episcleral venous pressure and decreasing the production of aqueous humor².

Indication: Netarsudil is used in open angle glaucoma or ocular hypertension for the purpose of elevated intraocular pressure¹ reduction.

Dosage: Netarsudil Ophthalmic solution containing 0.2 mg/mL

Pharmacokinetics: The systemic exposure of Netarsudil were evaluated in 18 adults and it was found that no quantifiable plasma concentration of netarsudil was found following the post dose day 1 and day 8. Metabolised by esterases in the eyes after ocular dosing¹.

Adverse effects: Most occurring ocular adverse effects with Netarsudil is conjunctival hyperemia, corneal verticillata, instillation site pain, conjunctival hemorrhage¹.

Nonclinical toxicology¹: Netarsudil is not mutagenic in mouse. Regarding carcinogenicity and fertility, long term studies have not been performed.

Uses in specific population¹: Pregnancy –Data is not available on Netarsudil for the use in pregnant women for any associated risk. In pregnant rats and rabbits, on i.v. administration during the period of organogenesis, **Netarsudil does not produce any fetal abnormalities.**

Geriatric Use¹: There was no differences in terms of safety or effectiveness have been observed between geriatric and other adult patients.

Clinical studies: Netarsudil was evaluated in three randomized and controlled trials, with open angle glaucoma or ocular hypertension patients. In Study 1 & 2 enrolled subjects with baseline IOP < 27mm hg and study 3 enrolled subjects with base line IOP < 30 mm hg. The duration was 3 months for study 1, 12 months for study 2 & 6 months for study 3. All three studies have demonstrated the reduction of IOP of 5mm hg for subjects treated with Netarsudil 0.02% once daily in the evening¹.

Conclusion: Netarsudil has a mechanism of action and it is unique through which it lowers the IOP. Also it has notable side effect of conjunctival hyperemia which could be treated by administering once in a day before bed time. In general, netarsudil may be helpful to the normotensive or steroid induced glaucoma² patients.

REFERENCES:

- 1) Product Information of Netarsudil – FDA
- 2) Dasso L, Al-Khaled T, Sonty S, Aref AA. Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date. Clinical Ophthalmology (Auckland, NZ). 2018;12:1939.